Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
Date:5/22/2013

NEW YORK, May 22, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NasdaqGS: AMAG -News).  The investigation focuses on whether the Company and its executives violated federal securities laws.

On May 22, 2013, Shares of AMAG dropped $2.69 or 10.73% during intraday trading after the company announced in regulatory filing that it has been made aware by Takeda Pharmaceutical Company Limited, the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso, ferumoxytol, from the Swiss market. This decision is based on a cluster of four post-marketing adverse event reports in Switzerland concerning hypersensitivity reactions of varying severity following the administration of Rienso from this batch.  One of these cases included a report of a fatality.

If you are aware of any facts relating to this investigation, or purchased shares of AMAG, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com

 


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
5. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
6. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
7. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
9. Physician-Patient Alliance for Health & Safety Announces Four Essentials for Safety for Patients Receiving Opioids
10. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
11. ELNs, Data Analytics, Knowledge Management: Trends, Challenges & Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):